-
Why You Should Retain DuPont Stock in Your Portfolio
2024 Jul 09, 12:23pm | 748DuPont de Nemours, Inc. (NYSE: DD) is expected to benefit from its innovation-driven investment, productivity actions and the acquisition of the Spectrum Plastics Group. However, it faces headwinds from certain challenges including weaker demand in specific businesses. The company's shares are...
-
Here's Why You Should Hold Onto Celanese Stock for Now
2024 Jul 09, 12:18pm | 853Celanese Corporation (NYSE: CE) is expected to benefit from its investments in high-return organic projects, cost and productivity actions and synergies of acquisitions. However, it faces headwinds from weak demand in certain end markets and pricing pressures. The company's shares have gained...
-
Should You Retain Trupanion Stock in Your Portfolio?
2024 Jul 08, 12:26pm | 833Trupanion, Inc. (NASDAQ: TRUP) has been benefiting from a focus on pet health and well-being in an underpenetrated pet insurance market, product launches, extended operating boundaries, as well as sufficient liquidity. Growth Projections The Zacks Consensus Estimate for Trupanion's 2024...
-
Natural Gas Markets Endure a Rocky Week: What Happened?
2024 Jul 08, 12:18pm | 901The U.S. Energy Department's weekly inventory release showed that natural gas supplies increased more than expected. The bearish inventory numbers, together with signs of production gains, affected natural gas futures, which settled with a heavy loss week over week. Meanwhile, forecasts for...
-
5 Financial Transaction Stocks in Focus Amid Digital Payment Boom
2024 Jul 05, 3:02pm | 1960The Financial Transaction Services industry is poised to benefit from the increasing adoption of digital solutions. A robust digital offering allows industry players to leverage this trend effectively. Favorable consumer spending patterns are expected to drive transaction volumes higher. To...
-
Quest Diagnostics to Expand in Canada With LifeLabs Buyout
2024 Jul 05, 12:46pm | 837Quest Diagnostics (NYSE: DGX) has entered into a definitive agreement with OMERS to acquire LifeLabs, a prominent Canadian provider of community laboratory tests. The deal, valued at approximately CAN $1.35 billion ($985 million), underscores DGX's strategy to expand its footprint in Canada...
-
Cirrus Logic Soars 54.6% YTD: Will the Upside Last?
2024 Jul 05, 11:44am | 884Cirrus Logic, Inc.'s (NASDAQ: CRUS) stock is continuing its upward trajectory, with a gain of 54.6% year to date (YTD) compared with 16.7% and 31.7% growth of the S&P 500 composite and the sub-industry, respectively. Cirrus Logic is a fabless semiconductor supplier that develops low-power,...
-
Should You Retain Markel Group Stock in Your Portfolio?
2024 Jul 03, 12:23pm | 802Markel Group Inc. (NYSE: MKL) has been gaining momentum on the back of new business volume, strong retention levels, an improving rate environment, higher interest income on cash equivalents, strategic buyouts and favorable growth estimates. Growth Projections The Zacks Consensus Estimate for...
-
Neuronetics Expands NeuroStar Portfolio With New Launch
2024 Jul 02, 4:08pm | 809Neuronetics, Inc. (NASDAQ: STIM) recently announced the nationwide launch of the Better Me Provider (BMP) program. The BMP program will be a part of the company's NeuroStar product line. The providers participating in the program are expected to maintain correct standards, developed in...
-
Mesoblast Soars 208% YTD on Positive Regulatory Updates
2024 Jul 02, 1:31pm | 740Mesoblast Limited (NASDAQ: MESO) has witnessed a phenomenal run in the year so far. Shares of MESO have risen a whopping 208.2% year to date against the industry's decline of 6.3%. The massive outperformance can mostly be attributed to positive regulatory updates. Image Source: Zacks...
-
Can Constellation Brands Beat Q1 Earnings Amid High Costs?
2024 Jun 28, 3:05pm | 916Constellation Brands, Inc. (NYSE: STZ) is scheduled to release first-quarter fiscal 2025 results on Jul 3, 2024. The alcoholic beverage bigwig is expected to have recorded top and bottom-line growth in the to-be-reported quarter. The Zacks Consensus Estimate for the company's fiscal first-...
-
Merck's New Pneumococcal Jab Capvaxive Gets CDC Panel Vote
2024 Jun 28, 12:34pm | 780Merck (NYSE: MRK) announced that the U.S. Centers for Disease Control and Prevention's (CDC) Advisory Committee on Immunization Practices (ACIP) has unanimously voted to recommend MRK's newly approved 21-valent pneumococcal conjugate vaccine (PCV) Capvaxive. The FDA approved Capvaxive...
-
Denali Outperforms Industry in 3 Months: Here's Why
2024 Jun 28, 11:46am | 928Denali Therapeutics Inc. (NASDAQ: DNLI) is having a good run in 2024. Shares of this biopharmaceutical company have risen 11.9% in the past three months against the industry's decline of 6%. Denali is developing a broad portfolio of product candidates engineered to cross the blood-brain barrier...
-
BlackBerry Q1 Earnings Beat Estimates, Revenues Down Y/Y
2024 Jun 27, 3:55pm | 909BlackBerry Limited (NYSE: BB) reported first-quarter fiscal 2025 (ended May 31) adjusted loss per share of 3 cents, narrower than the company's estimate of a loss per share of 4-6 cents. In the year-ago quarter, it reported non-GAAP earnings of 6 cents per share. The Zacks Consensus Estimate...
-
Beam Therapeutics Begins Dosing in Phase I/II AATD Study
2024 Jun 27, 2:47pm | 629Beam Therapeutics Inc. (NASDAQ: BEAM) announced that it has dosed the first patient in the phase I/II study, evaluating its investigational in vivo base editing therapy, BEAM-302, for the treatment of alpha-1 antitrypsin deficiency (AATD). The open-label, dose-escalation study will investigate the...
Coverage of Earnings Beats.